Enzyme Therapy Breakthrough Enhanced Protein for Rare Genetic Disease

Pompe disease is a rare but devastating genetic disorder that progressively destroys muscle tissue. Amicus Therapeutics presents an engineered version of acid alpha-glucosidase enzyme designed to overcome limitations of current enzyme replacement therapies, potentially improving outcomes for patients with this life-threatening condition.

The Problem

Pompe disease is a rare genetic disorder caused by deficiency or dysfunction of the enzyme acid alpha-glucosidase (GAA). This enzyme is responsible for breaking down glycogen – a storage form of glucose – within cellular lysosomes. Without functional GAA, glycogen accumulates to toxic levels in muscle and heart tissues, causing progressive muscle weakness, cardiac dysfunction, and respiratory failure. The disease exists in two forms: infantile-onset Pompe disease manifests within the first months of life with severe muscle weakness and cardiac involvement, often fatal by age two without treatment. Late-onset Pompe disease appears in older children or adults with progressive muscle weakness. Enzyme replacement therapy (ERT) with recombinant GAA has improved outcomes for Pompe patients, but limitations persist. Current enzyme replacement therapy has significant challenges: the therapeutic enzyme cannot efficiently cross from the bloodstream into muscle cells and lysosomes where it is needed; many patients develop immune responses against the foreign enzyme, reducing efficacy over time; and cardiac and respiratory muscle tissues may respond inadequately to standard ERT. Better enzyme versions that overcome these limitations could substantially improve patient outcomes.

What This Invention Does

Amicus has engineered an enhanced acid alpha-glucosidase protein designed to overcome the limitations of current enzyme therapies. The augmented enzyme incorporates modifications that improve cellular uptake, enhance trafficking to the lysosomal compartment, and potentially reduce immunogenicity. The engineering enhances the enzyme’s ability to reach target lysosomes within muscle cells where glycogen accumulation causes damage. The enhanced enzyme maintains enzymatic activity while improving biodistribution and cellular delivery. By engineering the protein structure and surface properties, Amicus has created a version that penetrates muscle tissue more effectively and reaches the intracellular compartments requiring enzymatic glycogen degradation. This translates to improved metabolic function in affected muscle and heart tissues. Clinical benefits from improved GAA delivery could include better preservation of muscle strength and function, reduced disease progression, improved cardiac outcomes, and potentially extended survival. The augmented enzyme approach represents advancement over standard ERT by addressing the fundamental delivery and efficacy limitations of current treatments.

Key Features

Enhanced Cellular Uptake. Engineered protein design improves cellular internalization and delivery to lysosomes.

Improved Muscle Penetration. Modified enzyme penetrates muscle tissue more effectively than standard GAA therapy.

Reduced Immunogenicity. Protein engineering may reduce immune system recognition, improving long-term tolerability.

Maintained Enzymatic Activity. Enhancements preserve the enzyme’s ability to degrade glycogen and restore metabolic function.

Broad Tissue Distribution. Improved delivery addresses cardiac, skeletal, and respiratory muscle involvement.

Who Is Behind It?

Amicus Therapeutics, Inc. is developing this innovation with inventors Hung V. Do, Richie Khanna, and Russell Gotschall. The company is based in United States. This patent application is a divisional of an earlier filing, indicating ongoing development and refinement of the core technology over multiple patent generations.

Why It Matters

While Pompe disease is rare, affecting approximately 1 in 40,000 births, the disease is severe enough to justify premium pricing for effective therapies. Current enzyme replacement therapies generate over USD 500 million annually despite the small patient population. An augmented enzyme offering superior outcomes could command premium pricing and potentially increase patient identification and treatment. The technology could also be applied to other lysosomal storage diseases.

Patent classifications focus on enzymes and proteins (A61K 38/47), muscle and metabolic disorder treatment (A61P 21/00), and therapeutic molecules (A61K 31/445, A61P 43/00, A61P 3/00). This positioning reflects the enzyme therapy innovation within the rare disease and genetic medicine fields.

---

AU 2026201393 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Pompe disease belongs to a family of over 70 lysosomal storage diseases, all caused by defects in enzymes that recycle cellular waste within lysosomes. Enzyme replacement therapy addresses these disorders by supplying a functional version of the missing enzyme intravenously.

The key challenge for Pompe ERT is delivering the enzyme to skeletal muscle cells in sufficient quantities. Current therapies rely on the mannose-6-phosphate receptor to guide uptake, but receptor expression is limited in muscle tissue. Engineered enzymes with enhanced receptor binding – like the modified acid alpha-glucosidase developed here – aim to overcome this fundamental delivery bottleneck.